290 related articles for article (PubMed ID: 22302417)
1. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.
Keystone EC; Kremer JM; Russell A; Box J; Abud-Mendoza C; Elizondo MG; Luo A; Aranda R; Delaet I; Swanink R; Gujrathi S; Luggen M
Ann Rheum Dis; 2012 Jun; 71(6):857-61. PubMed ID: 22302417
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.
Nash P; Nayiager S; Genovese MC; Kivitz AJ; Oelke K; Ludivico C; Palmer W; Rodriguez C; Delaet I; Elegbe A; Corbo M
Arthritis Care Res (Hoboken); 2013 May; 65(5):718-28. PubMed ID: 23097311
[TBL] [Abstract][Full Text] [Related]
4. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).
Kaine J; Gladstein G; Strusberg I; Robles M; Louw I; Gujrathi S; Pappu R; Delaet I; Pans M; Ludivico C
Ann Rheum Dis; 2012 Jan; 71(1):38-44. PubMed ID: 21917824
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of abatacept in rheumatoid arthritis: a review.
Khraishi M; Russell A; Olszynski WP
Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
[TBL] [Abstract][Full Text] [Related]
9. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
Reggia R; Franceschini F; Tincani A; Cavazzana I
J Rheumatol; 2015 Feb; 42(2):193-5. PubMed ID: 25512476
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
Genovese MC; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Porawska W; Box J; Legerton C; Nasonov E; Durez P; Aranda R; Pappu R; Delaet I; Teng J; Alten R
Arthritis Rheum; 2011 Oct; 63(10):2854-64. PubMed ID: 21618201
[TBL] [Abstract][Full Text] [Related]
11. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Genovese MC; Pacheco-Tena C; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente RM; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Elegbe A; Wong R; Li X; Banerjee S; Alten R
J Rheumatol; 2018 Aug; 45(8):1085-1092. PubMed ID: 29657147
[TBL] [Abstract][Full Text] [Related]
12. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC
Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912
[TBL] [Abstract][Full Text] [Related]
13. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B.
Kim PS; Ho GY; Prete PE; Furst DE
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1265-8. PubMed ID: 22392695
[TBL] [Abstract][Full Text] [Related]
15. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.
Weinblatt ME; Moreland LW; Westhovens R; Cohen RB; Kelly SM; Khan N; Pappu R; Delaet I; Luo A; Gujrathi S; Hochberg MC
J Rheumatol; 2013 Jun; 40(6):787-97. PubMed ID: 23588946
[TBL] [Abstract][Full Text] [Related]
16. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
Sibilia J; Westhovens R
Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S46-56. PubMed ID: 17977488
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
[TBL] [Abstract][Full Text] [Related]
19. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
Schiff M; Weinblatt ME; Valente R; van der Heijde D; Citera G; Elegbe A; Maldonado M; Fleischmann R
Ann Rheum Dis; 2014 Jan; 73(1):86-94. PubMed ID: 23962455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
